This Company Is Ready To Flood The US With Cheap HIV Drugs
India News | Ari Altstedter, Bloomberg | Tuesday December 5, 2017
Among the coconut plantations and beaches of South India, a factory the size of 35 football fields is preparing to churn out billions of generic pills for HIV patients and flood the US market with the low-cost copycat medicines.
Laurus Labs Makes Strong Market Debut, Shares Jump 16%
Business | Monday December 19, 2016
Laurus Labs makes active pharmaceutical ingredients or APIs that go into the making a range of medicines, chiefly HIV/AIDS drugs.
Laurus Labs IPO Fully Subscribed
Business | Thomson Reuters | Thursday December 8, 2016
Laurus Labs was selling up to Rs 300 crore in new shares and some its shareholders were selling about 24.1 million shares in a price range of Rs 426 to Rs 428 per share.
Laurus Labs IPO: Five Things To Know Before Investing
Business | Tuesday December 6, 2016
Hyderabad-based pharma company Laurus Labs launched its initial public offer (IPO) on Tuesday to raise Rs 1,330 crore from the primary markets.
Laurus Labs Garners Rs 395 Crore From Anchor Investors
Business | Press Trust of India | Tuesday December 6, 2016
The anchor investors included Goldman Sachs India, Nomura Trust and Banking, SBI Mutual Fund, DSP BlackRock and ICICI Prudential Mutual Fund.
Laurus Labs' Rs 1,332 Crore IPO To Hit Market This Week
Business | Press Trust of India | Sunday December 4, 2016
The IPO is scheduled to open on December 6 and close on December 8.
Laurus Labs Gets Sebi Nod For IPO
Business | Press Trust of India | Monday October 17, 2016
Hyderabad-based firm had filed IPO papers with Sebi in August. The markets regulator issued its final 'observations' on October 10 on the draft offer documents, which is necessary for any company to launch the public offer.
Lupin, 5 Other Pharma Firms Ink Licensing Pact With Medicines Patent Pool
Business | Press Trust of India | Thursday July 7, 2016
Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.
This Company Is Ready To Flood The US With Cheap HIV Drugs
India News | Ari Altstedter, Bloomberg | Tuesday December 5, 2017
Among the coconut plantations and beaches of South India, a factory the size of 35 football fields is preparing to churn out billions of generic pills for HIV patients and flood the US market with the low-cost copycat medicines.
Laurus Labs Makes Strong Market Debut, Shares Jump 16%
Business | Monday December 19, 2016
Laurus Labs makes active pharmaceutical ingredients or APIs that go into the making a range of medicines, chiefly HIV/AIDS drugs.
Laurus Labs IPO Fully Subscribed
Business | Thomson Reuters | Thursday December 8, 2016
Laurus Labs was selling up to Rs 300 crore in new shares and some its shareholders were selling about 24.1 million shares in a price range of Rs 426 to Rs 428 per share.
Laurus Labs IPO: Five Things To Know Before Investing
Business | Tuesday December 6, 2016
Hyderabad-based pharma company Laurus Labs launched its initial public offer (IPO) on Tuesday to raise Rs 1,330 crore from the primary markets.
Laurus Labs Garners Rs 395 Crore From Anchor Investors
Business | Press Trust of India | Tuesday December 6, 2016
The anchor investors included Goldman Sachs India, Nomura Trust and Banking, SBI Mutual Fund, DSP BlackRock and ICICI Prudential Mutual Fund.
Laurus Labs' Rs 1,332 Crore IPO To Hit Market This Week
Business | Press Trust of India | Sunday December 4, 2016
The IPO is scheduled to open on December 6 and close on December 8.
Laurus Labs Gets Sebi Nod For IPO
Business | Press Trust of India | Monday October 17, 2016
Hyderabad-based firm had filed IPO papers with Sebi in August. The markets regulator issued its final 'observations' on October 10 on the draft offer documents, which is necessary for any company to launch the public offer.
Lupin, 5 Other Pharma Firms Ink Licensing Pact With Medicines Patent Pool
Business | Press Trust of India | Thursday July 7, 2016
Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.
................................ Advertisement ................................
................................ Advertisement ................................
